Prostate Cancer International will be holding its next prostate cancer patient meeting (“Prostate Cancer Today: Living Well; Choosing Wisely”) on Saturday, November 2, 2019, in Virginia Beach, near Norfolk, Virginia, USA. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Choosing Wisely, conference, education, living well | 1 Comment »
Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy (ADT) among patients initially diagnosed with locally advanced (T3) prostate cancer? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: radiation, stage, surgery, T3, Treatment, trial | 2 Comments »
What celebs say and don’t say about prostate cancer (if they say anything at all) has often been difficult for the average patient to understand — as are some of their apparent treatment decisions (if those are actually mentioned). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: celebrity, spokeperson | 3 Comments »
In this week’s New England Journal of Medicine (NEJM), there is an interesting article entitled, “Contingent knowledge and looping effects — a 66-year-old man with PSA-detected prostate cancer and regrets”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "looping", context, contingent, data, interpretation, knowledge | 4 Comments »
Yesterday (September 17, 2019), the US Food and Drug Administration approved apalutamide (Erleada) for treatment of men with metastatic castration-sensitive prostate cancer (mCSPC) … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, Erleada, mCSPC, mHSPC, US | Leave a comment »
